[January 07, 2013]

Research and Markets: Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to 2022

Research and Markets (http://www.researchandmarkets.com/research/txs8gc/rencarex_renal) has announced the addition of GlobalData's new report "Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to 2022" to their offering.

Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to 2022 provides Torisel sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2022). The report also includes information on Renal Cell Carcinoma market.

Scope

- Theapy area profile including patient population for the US and EU5

- Analysis and review of Rencarex including sales data

- Qualitative and quantitative assessment of market space

- Analysis of the trends, drivers and restraints shaping and defining the markets

- In-depth analysis of Rencarex including efficacy, safety, pricing, competition and other details which influence its sales potential

- Detailed sales forecast for 2012-2022 for Rencarex in the US and EU5

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of competition by understanding the changing competitive landscape

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of the drug's performance

- Examine the historical sales performance of a drug in seven major markets

- Obtain sales forecast for currently marketed/pipeline drug for 2014-2022 for all seven major markets

For more information visit http://www.researchandmarkets.com/research/txs8gc/rencarex_renal

Source (News - Alert): GlobalData

[ Back To Technology News's Homepage ]